Analytical Data
-
Gene name
IMUP
- Application
-
Alternative Names
Hepatocyte growth factor activator inhibitor type 2-related small protein ;H2RSP ;HAI-2-related small protein
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9GZP8
-
Expression Region
1-85aa
-
Molecular Weight
35.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of IMUP (Immunomodulatory Protein) recombinant proteins stems from the growing need for therapeutic agents that modulate the immune response in various diseases, including cancer and autoimmune disorders. IMUP, a protein originally derived from specific biological sources, has shown promise in enhancing immune functions and regulating inflammatory processes. Researchers have been particularly interested in its potential to serve as an adjuvant in vaccines or as a standalone therapeutic agent that can restore immune balance. With advancements in recombinant DNA technology, scientists are now able to produce IMUP in a more efficient and scalable manner, enabling detailed studies on its structure-function relationship and biological activity. Preliminary studies have indicated that IMUP may enhance the proliferation of immune cells and promote cytokine production, highlighting its role in immune modulation. Furthermore, the ability to manipulate this protein through genetic engineering opens pathways to create variants with improved efficacy and stability. As a result, ongoing research aims to elucidate the underlying mechanisms of IMUP's action, evaluate its safety and efficacy in preclinical models, and explore its potential applications in clinical settings. This line of research not only contributes to our understanding of immune therapies but also paves the way for developing innovative treatments that leverage the body's immune system more effectively.
